CASE REPORT





Increased risk for thromboembolic events from combination of a gynecologic malignancy with severe acute respiratory syndrome coronavirus 2 infection: a case report

Alexandra Stefan^{1*}, Marija Petkovic², Alexander König¹, Julian Koch¹, Friederike Hagemann¹, Rachel Wuerstlein¹, Nadia Harbeck¹, Sven Mahner¹ and Till Kaltofen¹

Abstract

Purpose: During the severe acute respiratory syndrome coronavirus 2 pandemic, several patient groups are at particular risk. Mortality is higher among cancer patients and may be increased further by thromboembolic events, which are more common in coronavirus 2019 patients according to recent publications. We discuss the association of gynecologic malignancies, Severe acute respiratory syndrome coronavirus 2, and thromboembolism by reporting a case study and summarizing available literature.

Case report: A 71-year-old Caucasian patient with ovarian cancer receiving first-line chemotherapy was diagnosed with deep vein thrombosis and pulmonary embolism. Routine screening revealed infection with severe acute respiratory syndrome coronavirus 2 in absence of specific symptoms. After uneventful recovery, oncologic treatment could be continued a few weeks later.

Methods: We performed a systematic review of the literature on PubMed following Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. The search included articles ahead of print, published between 1 December 2019 and 1 June 2020. Cross-searches were conducted on all relevant articles.

Results: We identified five articles meeting the defined criteria, including two retrospective studies, a review, a position paper, as well as a letter to the editor.

Conclusion: Cancer patients infected with severe acute respiratory syndrome coronavirus 2 have a relatively poor outcome, which may partially be due to a higher rate of thromboembolic events. Thromboprophylaxis is recommended, and scoring systems are helpful in early detection. In cancer patients with severe acute respiratory syndrome coronavirus 2, individual risk for thromboembolic events should be taken into account when considering interruption versus continuation of antitumoral therapy. However, further data and studies are required.

Keywords: Ovarian cancer, Gynecologic malignancies, COVID-19, SARS-CoV-2, Thromboembolism, Review, Case report

Introduction

*Correspondence: Alexandra.Stefan@med.uni-muenchen.de ¹ Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany

Full list of author information is available at the end of the article



The world is experiencing a rapid spread of a novel virus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. By 1 November 2020, the World Health Organization reported 45,968,799

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

confirmed cases worldwide and 1,192,911 deaths due to coronavirus disease 2019 (COVID-19). Clinical symptoms partially overlap with other viral diseases: The most commonly reported symptoms are fever and cough as well as dyspnea, myalgia, confusion, diarrhea, nausea, and vomiting [2, 3]. The clinical course of the disease varies widely from asymptomatic to lethal [4]. Among others, male sex, older age, smoking, and presence of preexisting health conditions are described to adversely affect outcomes [5-9]. Cancer patients might be at increased risk of infection because of their higher morbidity as well as for being immunocompromised. They have repeatedly been reported to have a poorer clinical outcome [10, 11], especially in the setting of metastatic disease or recent surgery [12]. Regarding cancer in women, Mehta et al. reported a mortality rate of 14% for COVID-19 patients suffering from breast cancer and of 38% for patients suffering from pelvic gynecologic cancers [13].

As malignancies may affect all three arms of Virchow's triad, patients with active cancerous disease are at elevated risk for venous thromboembolism (VTE) [14]. Presumably, 20–30% of all first thromboembolic events are cancer associated, making malignancies one of the best-established risk factors for VTE [15].

Recently, there has been growing evidence that the incidence of thromboembolic complications in critically ill COVID-19 patients is remarkably high [16-20]. Angiotensin-converting enzyme 2 (ACE2) is recognized as an important receptor used by SARS-CoV2 [21]. ACE2 protein is eminently expressed on arterial and venous endothelial cells. There is evidence of direct viral infection of endothelial cells [22] as well as indicators for microvascular injury syndrome mediated by activation of complement pathways [23]. Both can explain a procoagulant state in COVID-19 patients. Abnormal coagulation parameters, such as elevated D-dimer levels, are found to be associated with poor prognosis for COVID-19 patients [24–26]. Conversely, patients with a severe course of COVID-19 are more frequently diagnosed with disseminated intravascular coagulation [27].

The interrelationship between cancer-related hypercoagulopathy and SARS-CoV-2 in oncological patients therefore requires special attention. Here, we report the case of a patient suffering from high-grade serous ovarian cancer (HGSOC) who was admitted to our hospital with pulmonary embolism (PE) and COVID-19 during the SARS-CoV-2 pandemic in April 2020. To give an overview of what is known about the combination of a gynecologic malignancy, a VTE event, and COVID-19, we summarize available literature and elaborate on possible problems.

Case report

A 71-year-old Caucasian woman, gravida 2/para 2, presented with pain in her lower left leg accompanied by progressive dyspnea in April 2020. She had already received dabigatran prescribed by her general practitioner for suspected deep vein thrombosis (DVT) one day prior to her admittance.

The patient was undergoing multimodal treatment at our clinic for HGSOC FIGO IIIC. Up to that point, she had received debulking surgery with macroscopic complete tumor resection in February 2020, including bilateral adnexectomy, hysterectomy, peritonectomy, infragastric omentectomy, pelvic and paraaortic lymphadenectomy, partial liver resection, and rectosigmoid resection. Secondary wound closure could be achieved after treatment of wound dehiscence in March 2020. First-line chemotherapy was initiated with carboplatin AUC 5 and paclitaxel 175 mg/m² every 3 weeks. After completion of the first course, we switched to weekly application of carboplatin AUC 2 and paclitaxel 80 mg/ m² to improve tolerability. Three weekly courses of chemotherapy were administered without complications. Initiation of bevacizumab was postponed due to delayed wound healing. The patient reported a general feeling of weakness since surgery but was otherwise in a good state of health.

Her medical history included papillary thyroid cancer, successfully treated in 2008 by total thyroidectomy, and catheter ablation of the AV node because of atrioventricular nodal reentry tachycardia in 2015. No other relevant cardiovascular or pulmonal diseases were known. She had an uneventful gynecological and obstetrical history. *BRCA* testing was negative, and there was no family history of gynecologic malignancies. The patient did not smoke or drink alcohol regularly. She was taking L-thyroxin, pantoprazole, and vitamin D as regular medication.

At current presentation, she was routinely asked for symptoms and risk factors for COVID-19 and negated symptoms such as fever, cough, headaches, loss of taste or smell, or recent international travel. Her only contacts were close relatives as well as her general practitioner. Clinical examination showed normal clinical conditions as well as normal vital functions (blood pressure 123/75 mmHg, temperature 36.9 °C, heart rate 87 /minute, oxygen saturation 98 %) but a slightly elevated respiratory rate (22 /minute). Besides chronic anemia (hemoglobin 9.0 g/dl) and elevated infection parameters (C-reactive protein 8.1 mg/dl, ferritin 470 ng/ml), blood testing showed no relevant changes; especially, renal and hepatic function were normal. Sonography revealed a mild urinary stasis on the left side.

For further diagnosis, we referred the patient to the angiology department of our clinic, where DVT of the left lower leg as well as a thrombophlebitis of the right great saphenous vein and venous thrombosis of the right gastrocnemius muscle vein were confirmed via color Duplex sonography. We ordered chest computed tomography due to complaints of progressive dyspnea, revealing segmental PE in one central lung artery as well as in several subsegmental arteries (Fig. 1a). No infiltrates, especially no changes typical for COVID-19, were seen (Fig. 1b). We performed a nasopharyngeal swab as a routine screening test for SARS-CoV-2 upon hospitalization. Surprisingly, it revealed infection with SARS-CoV-2 via reverse-transcription polymerase chain reaction (PCR) testing on the following day. The woman was therefore isolated and transferred to the infectiology department of our clinic, where she was treated for ten more days. As the patient was in a stable cardiopulmonal condition with no signs of right heart overload in echocardiography, conservative treatment with low-molecular-weight heparins (LMWH) at a therapeutic dosage and compression stockings was continued. Respiratory parameters were sufficient with no need for oxygen therapy or further medication at any time. An incidental urinary tract infection with Klebsiella pneumonia was sufficiently treated with cefpodoxim 400 mg per day for 10 days.

A repeat PCR test before discharge was negative. The patient was quarantined at home for 14 more days. Anticoagulant treatment was continued with apixaban for 6 months. No further thromboembolic events occurred meanwhile. With a therapeutic gap of 5 weeks, we continued chemotherapy with the weekly regimen. For the next 2 courses, dose reduction to 75% was performed; full doses of carboplatin AUC 2 and paclitaxel 80 mg/ m² were resumed thereafter and well tolerated. A lymphocele of the left lower abdomen which had caused progressive urinary stasis was drained complication-free 5 months later. As bevacizumab was contraindicated because of prior VTE, oncologic maintenance therapy with niraparib 200 mg per day followed afterwards.

Methods

For the systematic literature review according to PRISMA guidelines, we performed a comprehensive bibliographic search of PubMed limited to articles published from 1 December 2019 to 1 June 2020, using the following string term: [(lung artery embolism) OR (thromboembolism) OR (thrombotic) OR (thrombosis) OR (coagulopathy)) AND ((corona) OR (COVID 19) OR (SARS)] AND [(cancer) OR (oncology) OR (malignancy) OR (malignant)]. We did not limit our search to gynecologic malignancies due to the paucity of data. For the same reason, we also included articles ahead of print at the current time. The search generated 37 results, whose full texts were evaluated for relevance with respect to all three topics. Subsequently, we performed a cross-reference search of all relevant articles (Fig. 2).

Results

The majority of articles were excluded as they did not focus on associating all three topics, or only briefly mentioned or cited one of the selected search terms without going into detail. Four research articles remained, including a retrospective study [28], a review on risk of thromboembolism in COVID-19 patients [29], a position paper on COVID-19 and hemostasis [30], as well as a letter to the editor referring to the risk of thrombotic events



Page 4 of 7

during systematic oncological treatment in COVID-19 patients [31]. The cross-reference search revealed one more retrospective study on risk assessment of VTE on COVID-19 patients meeting the inclusion criteria [32] (Fig. 2).

Xu *et al.* investigated the role of risk factors for VTE on clinical outcomes of 138 COVID-19 patients in a retrospective study. They found that critically ill patients are more likely to have malignancy as risk factor than non-critically ill patients (6.7% versus 2.4%), and the same could be obtained in patients with active cancer (6.7% versus 0.0%) [32].

Furthermore, Criel *et al.* reported 52 cases of COVID-19 patients receiving general inpatient care, two of whom had insidious VTE of the upper and lower limbs. One of these two patients suffered from active stage IV cancer of unreported origin. However, presence of PE was not investigated in this study. The incidence of thromboembolic events may therefore be underestimated [28].

Khan *et al.* focused on the diagnosis of VTE, discussing possible pathomechanisms in COVID-19 patients. The

authors further outline the need for scoring systems to more reliably detect VTE, especially if risk factors such as malignancies preexist. They also give an overview about different challenges and management of VTE in COVID-19 patients and recommend generous use of thromboprophylaxis to improve patients' outcome [29].

The Italian Society on Thrombosis and Haemostasis gives specific recommendations concerning the treatment of hemostasis imbalance in COVID-19 patients based on expert consensus. As patients with active cancer face an increased risk of VTE, thromboprophylaxis is suggested not only for the entire duration of their hospital stay but also in the time preceding and following it. The use of intermediate-dose LMWH should be evaluated based on individual risk factors [30].

The letter to the editor discusses an infection with SARS-CoV-2 in cancer patients treated with prothrombotic drugs such as tyrosine kinase inhibitors. As a possible synergistic risk increase for VTE should be avoided, timely interruption of treatment with prothrombotic



drugs in patients with suspected SARS-CoV-2 infection must be considered [31].

Discussion

We report herein a case demonstrating the relevance of elevated risk of VTE in cancer patients within the context of the ongoing SARS-CoV-2 pandemic. The systematic literature review illustrated that research into this topic is still in its infancy.

Several studies indicate that cancer patients suffering from COVID-19 face a less favorable prognosis, marked by increased requirement of intensive care treatment and mechanical ventilation as well as increased mortality [10, 11]. Breast cancer and malignancies of the female reproductive tract accounted for more than 38.6% of new cases of cancer among women and were responsible for over 29.1% of deaths resulting from cancer in 2018 [33]. Due to their incidence and their intrinsically high mortality rate, gynecologic malignancies are of particular interest in the context of SARS-CoV-2.

Leaving aside her underlying oncologic condition, despite infection with SARS-CoV-2, our patient was not in a critical health condition but rather presented without any typical symptoms of COVID-19 apart from mild dyspnea and tachypnea. Indeed, 17.9–20.8% of patients were described to be asymptomatic in recent studies [34, 35]. The authors suspect this to be due to a weaker immune response to SARS-CoV-2. However, it is unclear whether the putative increase of thrombotic complications associated with COVID-19 is less likely in asymptomatic or mild symptomatic patients as our case demonstrates a syncronous occurrence.

Interestingly, Miyashita *et al.* recently reported that cancer patients required invasive mechanical ventilation more frequently, but were less likely to die from COVID-19, albeit not to a statistically significant extent [36]. Some researchers attribute this to the impaired immune system of oncologic patients decreasing the risk of a hyperinflammatory syndrome [36, 37], which is discussed as a relevant cause of death in COVID-19 patients [38, 39].

Still, other authors reported elevated mortality rates for cancer patients [10, 12]. According to our findings, this may be explained by an increased risk for thromboembolism: We identified two studies reporting retrospective data, suggesting that VTE might worsen the outcome of oncologic patients or might even unfavorably influence their prognosis in case of SARS-CoV-2 infection [28, 32]. However, we found that the data available so far are insufficient and do not allow for a reliable interpretation of the role of hypercoagulability in this context.

Presumably, due to the rudimentary state of research, no specific data concerning gynecologic tumors are

available yet. However, more information on this topic is urgently needed, as ovarian and uterine cancers are described to be associated with a comparatively high risk for VTE compared with other types of cancer [40]. In a study by Saadeh et al., the risk for VTE in patients with ovarian cancer was up to 9.7% [41]. Aside from a more advanced stage and a higher tumor grade, undergoing complex surgery and chemotherapy are relevant risk factors. Consequently, our patient already had a high risk of VTE. It is not possible to ascertain whether infection with SARS-CoV-2 played a decisive role, but considering the findings of the literature review, at least a synergistic mechanism is certainly conceivable. Consequently, it has to be assumed that administration of bevacizumab, a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody with high prothrombotic potential [42, 43], would have further increased the risk of VTE and might have worsened the clinical outcome. A possible additional detrimental effect from oncologic drugs should be taken seriously when discussing COVID-19 in cancer patients. Potential benefits of interrupting oncological therapy in suspected cases as described by da Fonseca and Carrilho [31] need to be weighed against possible risks.

Using scoring systems for risk stratification as well as detection of VTE in COVID-19 patients in a timely manner as suggested by Khan et al. [29] seems to be a useful proposal in this and any other setting. The assumed elevated risk of cancer patients for VTEs has already attracted attention and led to specific recommendations concerning anticoagulant treatment in case of SARS-CoV-2 infection [30]. So far, these recommendations are based on expert consensus, and further data from clinical trials are needed to gain higher evidence. For instance, COVID-19 patients are reported to develop life-threatening thrombotic complications despite anticoagulant thromboprophylaxis [20]. On the other hand, there is promising data suggesting an improved outcome of hospitalized patients with COVID-19 receiving systemic anticoagulation at therapeutic doses [44]. Indeed, the potential benefits of anticoagulation need to be weighed against the risk of bleeding, which is increased in cancer patients, in particular after large surgical interventions, and would be increased further by anticoagulation [45].

Many authors have noted that the major risk for both cancer and VTE patients might be the inability to receive necessary medical services during this pandemic [46]. Consequently, the possibility of reduced quality of care might result in a deterioration of midand long-term results of cancer treatment [47].

Conclusion

The reported case illustrates that cancer patients are at special risk regarding morbidity and mortality during the SARS-CoV-2 pandemic. Relevant factors in this context appear to be the combined prothrombotic potential of the viral disease, the oncologic disease itself, and the accompanying drug therapy. This applies to gynecologic tumors in particular, which account for a substantial part of incidence and mortality due to malignant disease in women. Therefore, they are of special interest in this context.

To carefully weigh opportunities and risks and to give reliable therapy recommendations for cancer patients during the SARS-CoV-2 pandemic, more data and studies are required. Already established international registries are an important step in this direction [48].

Abbreviations

COVID-19: Coronavirus disease 2019; DVT: Deep vein thrombosis; HGSOC: High-grade serous ovarian cancer; LMWH: Low-molecular-weight heparins; PE: Pulmonary embolism; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; VEGF: Vascular endothelial growth factor; VTE: Venous thromboembolism.

Acknowledgements

We thank the patient for her consent to discuss her medical case in this article.

Authors' contributions

Conceptualization: AS, JK, MP, AK, and TK; Methodology: FH and RW; Investigation and formal analysis: AS, MP, AK, JK and TK; Writing and original draft preparation: AS; Review and editing: NH, SM and TK; Supervision: FH, RW and TK. All authors analyzed and interpreted the data and read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Informed consent was obtained from the patient included in the study.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

Rachel Wuerstlein reports grants and personal fees from Agendia, Amgen, Aristo, AstraZeneca, Boeringer Ingelheim, Carl Zeiss, Celgene, Clinsol, Daiichi-Sankyo, Eisai, Genomic Health, Glaxo Smith Kline, Hexal, Lilly, Medstrom Medical, MSD, Mundipharma, Nanostring, Novartis, Odonate, Paxman, Palleos, Pfizer, Pierre Fabre, and Puma Biotechnology outside the submitted work. Nadia Harbeck reports personal fees from Amgen, AstraZeneca, Celgene, Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Samsung, and Sandoz outside the submitted work. Sven Mahner reports grants and personal fees from AstraZeneca, Clovis, Medac, MSD, PharmaMar, Roche, Sensor Kinesis, Tesaro and Teva outside the submitted work. The other authors declare no conflict of interest.

Page 6 of 7

Author details

¹Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany. ²Department of Medicine IV, University Hospital, LMU Munich, Munich, Germany.

Received: 23 June 2021 Accepted: 19 February 2022 Published online: 22 March 2022

References

- Bikdeli B, Madhavan MV, Gupta A, Jimenez D, Burton JR, Der Nigoghossian C, et al. Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research. Thromb Haemost. 2020;120(7):1004.
- Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13.
- Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical characteristics of Covid-19 in New York city. N Engl J Med. 2020;382(24):2372–4.
- Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.
- Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, *et al.* Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110–8.
- Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81(2):e16-25.
- Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116(10):1666–87.
- Imam Z, Odish F, Gill I, O'Connor D, Armstrong J, Vanood A, *et al*. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. J Internal Med. 2020;288(4):469–76.
- Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052–9.
- Liang W, Guan W, Chen R, Wang W, Li J, Xu K, *et al.* Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–7.
- 11. Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, *et al.* Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31(7):894–901.
- 12. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, *et al.* Patients with cancer appear more vulnerable to SARS-COV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783–91.
- Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov. 2020;10(7):935–41.
- Levitan N, Dowlati A, Remick S, Tahsildar H, Sivinski L, Beyth R, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78(5):285–91.
- Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122(10):1712–23.
- Klok F, Kruip M, Van der Meer N, Arbous M, Gommers D, Kant K, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–7.
- Klok F, Kruip M, Van Der Meer N, Arbous M, Gommers D, Kant K, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020;191:148–50.
- Wichmann D, Sperhake J-P, Lütgehetmann M, Steurer S, Edler C, Heinemann A, *et al.* Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Internal Med. 2020;173(4):268–77.

- Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MC, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1995–2002.
- Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intens Care Med. 2020;46(6):1089–98.
- Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensinconverting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–4.
- Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–8.
- Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1–13.
- 24. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.
- Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboenbolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421–4.
- Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Internal Med. 2020;180(7):934–43.
- Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–7.
- Criel M, Falter M, Jaeken J, Van Kerrebroeck M, Lefere I, Meylaerts L, *et al.* Venous thromboembolism in SARS-CoV-2 patients: only a problem in ventilated ICU patients, or is there more to it? Eur Respir J. 2020;56:1.
- Khan IH, Savarimuthu S, Leung MST, Harky A. The need to manage the risk of thromboembolism in COVID-19 patients. J Vasc Surg. 2020;72(3):799–804.
- Marietta M, Ageno W, Artoni A, De Candia E, Gresele P, Marchetti M, et al. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfus. 2020;18(3):167.
- da Fonseca L, Carrilho FJ. Can thrombotic events be a major concern in hepatocellular carcinoma patients under systemic treatment during SARS-Cov-2? Liver Int. 2020.
- 32. Xu J-f, Wang L, Zhao L, Li F, Liu J, Zhang L, *et al*. Risk assessment of venous thromboembolism and bleeding in COVID-19 patients. 2020.
- Ferlay JEM, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. https://gco.iarc.fr/today (2018), accessed 09 November 2020.
- Long Q-X, Tang X-J, Shi Q-L, Li Q, Deng H-J, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200–4.
- Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Eurosurveillance. 2020;25(10):2000180.
- Miyashita H, Mikami T, Chopra N, Yamada T, Chernyavsky S, Rizk D, et al. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann Oncol. 2020;31(8):1088–9.
- Xia Y, Jin R, Zhao J, Li W, Shen H. Risk of COVID-19 for cancer patients. Lancet Oncol. 2020;21(4):1.
- Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England). 2020;395(10229):1033.
- Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun. 2020;111:102452.
- Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458–64.

- Saadeh FA, Norris L, O'Toole S, Gleeson N. Venous thromboembolism in ovarian cancer: incidence, risk factors and impact on survival. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):214–8.
- Chen N, Ren M, Li R, Deng X, Li Y, Yan K, et al. Bevacizumab promotes venous thromboembolism through the induction of PAI-1 in a mouse xenograft model of human lung carcinoma. Mol Cancer. 2015;14(1):140.
- Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300(19):2277–85.
- Paranjpe I, Fuster V, Lala A, Russak A, Glicksberg BS, Levin MA, et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol. 2020;76(1):122–4.
- 45. Kamphuisen PW, Beyer-Westendorf J. Bleeding complications during anticoagulant treatment in patients with cancer. Thromb Res. 2014;133:549–55.
- 46. Wang H, Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol. 2020;21(4):e181.
- 47. Pellino G, Spinelli A. How coronavirus disease 2019 outbreak is impacting colorectal cancer patients in Italy: a long shadow beyond infection. Dis Colon Rectum. 2020;63(6):720–2.
- Pinato DJ, Zambelli A, Bower M, Sng CC, Salazar R, Bertuzzi A, et al. Clinical portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer. Cancer Discov. 2020;10(10):1465–74.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

